Moreover, a personized risk assessment, including family history of premature ASCVD, chronic inflammatory diseases, other biomarkers (i.e., lipoprotein (a) and high-sensitivity C-reactive protein), and the presence of subclinical atherosclerosis detected by carotid ultrasound scan and coronary artery calcium scanning, should be also considered to guide TG-lowering treatment and physician–patient discussion [15]. Here, CRP is linked to atherosclerosis.